http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2019273656-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35c550f26f7794479dd8b8c0206034a0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate | 2019-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88d647c6568ef5eed94c19c6cd0581f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fdd36bf92cd4595267835a1a1b80150 |
| publicationDate | 2021-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2019273656-A1 |
| titleOfInvention | Pharmaceutical compounds for use in treating Huntington's disease |
| abstract | The invention provides (+)-α-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for use in reducing the life-shortening effect of Huntington's Disease in mammals. Also provided by the invention are(+)-α-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for use in preventing or delaying the onset of late stage Huntington's Disease; or for use in preventing or delaying the onset of life-threatening symptoms or events exhibited during late stage Huntington's disease. |
| priorityDate | 2018-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.